Both genetic knockdown and pharmacological inhibition of SIRT1 in CML CD34+ cells resulted in the acetylation and activation of p53, and subsequent upregulation of downstream pro-apoptotic factors (Li et al., 2012). The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.